Skip to main content

Zephyrus Innovations appoints David Whitaker as Chief Technology Officer

Vancouver, Canada – 30 May 2023: Zephyrus Innovations (Zephyrus), a privately-owned medical device company designing and manufacturing safety syringes and Closed System Transfer Devices (CSTDs), today announces the appointment of David Whitaker as Chief Technology Officer.

David brings with him more than 20 years’ experience in the development and manufacture of medical devices. Until recently, he was Operations Director at Atlas Genetics / Binx Health Ltd. where he took the Company’s first product, a point of care PCR system for the detection of infectious diseases, from prototype through to commercial supply. 

Zephyrus recently announced it had received its first product 510(k) Marketing Clearance from the US Food and Drug Administration (FDA) for its Aeroject™ 3ml safety syringe, the first device in a generation of safety syringes being developed by Zephyrus. 

In a global market expected to reach c.$8.5 billion by 2024, with the US accounting for 40% of sales, demand for safety syringes is growing. Safety syringes are critical to healthcare workers. Less than 33% of safety syringes sold are automatic retracting needles, with the majority requiring cumbersome, manual intervention. Poor safety outcomes can be costly and deadly due to potential transmission of bloodborne pathogens, and with increasing regulation, there is a growing threat of class action lawsuits. There has never been a greater demand for syringes that improve the safety of clinicians. 

Guy Reynolds, Chief Executive Officer of Zephyrus, said: “We are thrilled that David is joining the team at Zephyrus. He brings considerable expertise that will be crucial as we move through the regulatory process on a number of products in our pipeline. Zephyrus is a growing business developing its a range of Aeroject safety syringes and Closed System Transfer Device and David’s appointment will build on the strength of our management team as the business moves forward at this exciting time.

David Whitaker, Chief Technology Officer of Zephyrus, added: “Zephyrus is an exciting company and I am joining the team at a pivotal time, as it seeks to develop its innovative, next-generation retractable device, bringing real benefits to patients, clinicians and healthcare providers alike. The market opportunity for retractable safety syringes is huge and I look forward to playing a part in bringing these much-needed products to the market and the benefits that these will bring to both healthcare workers and patients.”

Zephyrus’ syringes are for general medical use in healthcare facilities by medical professionals for paediatric and adult population patients for aspiration and injection of fluids.